Clinical Validation of HPV ctDNA for Early Detection of Residual Disease Following Chemoradiation in Cervical Cancer.

K Han, J Zou, Z Zhao, Z Baskurt, Y Zheng, T Barnes,J M Croke, A Fyles,A P Gladwish, M Lecavalier-Barsoum,J Lukovic, E L Marchand,M Milosevic,A Taggar,S V Bratman,E W Leung

International journal of radiation oncology, biology, physics（2023）

Cited 0|Views5

No score

Abstract

HPV-seq enables HPV genotyping directly from plasma in locally advanced cervical cancer. Persistent HPV ctDNA following CRT is independently associated with inferior PFS in this prospective validation study. HPV ctDNA testing can be used to identify, as early as at the end of CRT, patients at high risk of recurrence in future treatment intensification trials.

Translated text

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined